Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit

San Diego, CA, and Bergisch Gladbach, Germany – September 15, 2026 – Tr1X, Inc. and Miltenyi Biotec today announced that they will highlight their collaboration to support the development and manufacturing of Tr1X’s allogeneic Tr1 and CAR-Tr1 Treg cell therapy programs at the 11th Annual CAR-TCR Summit, taking place September 15–17, 2026, in Boston, Massachusetts.

The collaboration demonstrates how strategic manufacturing partnerships can help emerging cell therapy companies establish a path toward clinical development while maintaining the flexibility and scalability needed as programs advance.

From clinical development to future scale

Tr1X is developing a clinical-stage pipeline of allogeneic and in vivo Tr1 and CAR-Tr1 Treg cell therapies for immune-mediated and inflammatory diseases. Through its collaboration with Miltenyi Biotec, Tr1X has established a manufacturing approach designed to support clinical development today while providing a foundation for future scale.

The presentation will describe how the integrated cell and gene therapy offering from Miltenyi Biotec, spanning vector design and manufacturing, process development, contract manufacturing, analytics, regulatory support, and automated manufacturing technologies, can help accelerate clinical readiness and support future scale-up for allogeneic cell therapy programs.

“Having the right manufacturing strategy in place early is critical as we advance our allogeneic cell therapy programs toward the clinic,” said James Adams, Chief Technical Officer, Tr1X, Inc. “Our collaboration with Miltenyi Biotec has helped us build a manufacturing approach that supports our clinical objectives while giving us a path toward future scale.”

A partnership designed for long-term development

For emerging cell therapy companies, establishing manufacturing capabilities can require significant investment, specialized expertise, and infrastructure. Working with an experienced manufacturing partner can provide greater flexibility while allowing companies to focus resources on clinical development and advancing their pipeline.

“Tr1X is a strong example of how close collaboration between a therapy developer and manufacturing partner can help address the challenges of bringing allogeneic cell therapies toward the clinic,” said Leonard Pulig, President and General Manager, Miltenyi Biotec, Inc. “We are pleased to support Tr1X as they advance their programs and establish a manufacturing foundation designed to evolve with their development needs.”

The presentation will explore lessons from the collaboration, including the importance of aligning manufacturing strategy with clinical objectives, building scalability into the development process, and establishing the right operating model as cell therapy programs progress.

Join Tr1X at the 11th Annual CAR-TCR Summit

Presentation: Partnering for Scale: Maximizing Allogeneic Cell Therapy Success Using the Right CDMO
Speaker: James Adams, Chief Technical Officer, Tr1X, Inc.
Date: Thursday, September 17, 2026
Time: 11:25 a.m. (EDT)
Location: The Westin Boston Seaport District, Boston, Massachusetts

The presentation will take place during the Early-Stage Manufacturing Track and will address three key considerations for allogeneic cell therapy developers: (i) accelerating the path to the clinic, (ii) designing manufacturing for future scalability and (iii) determining the right manufacturing operating model as programs mature.

About Miltenyi Biotec

Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, turning scientific discoveries into practical treatments for personalized medicine. Having pioneered a groundbreaking method of cell separation, Miltenyi Biotec continues to set industry standards today. With over 35 years of expertise, it supports customers in biomedical discoveries, translating them into clinical applications to enable access to new therapies for patients. Miltenyi Biotec focuses on providing integrated, advanced solutions to address complex challenges in the treatment of cancers, autoimmune diseases, and inherited disorders. Through its Miltenyi Bioindustry division, it provides expert guidance to therapy developers, helping them efficiently and cost-effectively navigate the path from process development to commercialization. Miltenyi Biotec is headquartered in Bergisch Gladbach and has a global team of 5,000 employees across 24 countries.

Go to www.miltenyibiotec.com or follow Miltenyi Biotec on LinkedIn to get the latest updates.

About Tr1X, Inc.

Tr1X is a clinical-stage biotechnology company developing engineered Tr1 cell therapies to restore immune balance in autoimmune and inflammatory diseases. Leveraging the unique biology of Tr1 cells, the company is advancing a pipeline of off-the-shelf allogeneic and in vivo CAR-Tr1 therapies designed to deliver targeted immunoregulation and address diseases driven by immune dysfunction, including transplant-related complications. Founded by pioneers in the discovery of Tr1 cells, Tr1X is focused on developing durable, potentially curative therapies for conditions with high unmet medical need. Tr1X is backed by leading investors, including The Column Group, NEVA SGR, and Alexandria Venture Investments, and has received grant support from the California Institute for Regenerative Medicine (CIRM). For more information, visit www.tr1x.bio.

Media contacts

Miltenyi Biotec
Kim Münster
Manager, Corporate Communications
corpcom@miltenyi.com

Tr1X, Inc.
press@tr1x.bio